Wise-Draper, T., Bell, D., Jandarov, R., Gulati, S., Gillison, M., Takiar, V., . . . Lee, J. J. (2020). 809 Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival. BMJ Publishing Group.
Chicago Style (17th ed.) CitationWise-Draper, Trisha, et al. 809 Phase 2 Trial of Neoadjuvant and Adjuvant PD-1 Checkpoint Blockade in Local-regionally Advanced, Resectable HNSCC Indicates Pathological Response Is Associated with High Disease-free Survival. BMJ Publishing Group, 2020.
MLA (8th ed.) CitationWise-Draper, Trisha, et al. 809 Phase 2 Trial of Neoadjuvant and Adjuvant PD-1 Checkpoint Blockade in Local-regionally Advanced, Resectable HNSCC Indicates Pathological Response Is Associated with High Disease-free Survival. BMJ Publishing Group, 2020.